Current status of newer antiinfectives

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 3, 2008, Pages 206-224

  Wattal, Chand ^a   Oberoi, Jaswinder K ^a   Raveendran, Reena ^a   Prasad, Kamal J ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

Antiparasitic patents; Daptomycin; Echinocandins; Ertapenem; Gemifloxacin; Tigecycline; Voriconazole

Indexed keywords

AMODIAQUINE; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; ARTEETHER; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; AZTREONAM; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CILASTATIN PLUS IMIPENEM; DAPTOMYCIN; ERTAPENEM; FANSIDAR; GEMIFLOXACIN; INVAZ; IVERMECTIN; KALSOME; MEFLOQUINE; MILTEFOSINE; MOXIDECTIN; NITAZOXANIDE; PAROMOMYCIN; PLACEBO; QUININE; TETRACYCLINE; TIGACIL; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ABDOMINAL CRAMP; ABDOMINAL INFECTION; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMEBIASIS; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASCARIASIS; ASCOMYCETES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASTHENIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BLURRED VISION; BONE INFECTION; BRAIN MALARIA; CANDIDEMIA; CANDIDIASIS; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CESTODIASIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; COLOR VISION; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; CRYPTOCOCCOSIS; CRYPTOSPORIDIOSIS; DERMATITIS; DIAPHRAGM PARALYSIS; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC BURNING; ESOPHAGITIS; EYE TOXICITY; FASCIOLIASIS; FATIGUE; FILARIASIS; FOOD; FOOD DRUG INTERACTION; FUSARIUM; GAIT DISORDER; GASTROINTESTINAL DISEASE; GIARDIASIS; HALF LIFE TIME; HEARING IMPAIRMENT; HEART PALPITATION; HOSPITAL INFECTION; HUMAN; HYPERNATREMIA; HYPOKALEMIA; INFECTION PREVENTION; INFECTIOUS ARTHRITIS; INSOMNIA; INTESTINE INFECTION; LEISHMANIASIS; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TOXICITY; MALARIA; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; MEASLES LIKE RASH; MUSCLE WEAKNESS; MYALGIA; MYCOSIS; MYDRIASIS; NAUSEA; NEMATODIASIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ONCHOCERCIASIS; OTOTOXICITY; PARESTHESIA; PATIENT COMPLIANCE; PELVIC INFLAMMATORY DISEASE; PHLEBITIS; PHOTOPHOBIA; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; PLASMA PROTEIN BINDING; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PRURITUS; QT INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SCEDOSPORIUM; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SKIN LEISHMANIASIS; SLEEP DISORDER; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STOMATITIS; TAENIASIS; TERATOGENICITY; THROMBOPHLEBITIS; TRICHOMONIASIS; ULCER; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URTICARIA; VISCERAL LEISHMANIASIS; VISUAL DISORDER; VOMITING;

EID: 58149176763     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108786242404     Document Type: Review

References (79)

1. Shah PM, Isaaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-543.
2. Cunha BA. Ertapenem: A review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today (Barc) 2002; 38: 195-213.
3. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-3511.
4. Legua P, Lema J, Moll J, et al. Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Clin Ther 2002; 24: 434-444.
5. Livermore DM, Oakton KJ, Carter MW, et al. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent blactamases. Antimicrob Agents Chemother 2001; 45: 2831-2837.
6. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactum in the treatment of complicated intra abdominal infections. Results of a double-blind, randomized comparative Phase III tria. Ann Surg 2003; 237: 235-245.
7. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactum 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of aprospective, randomized, double-blind multicenter study. Clin Infect Dis 2002; 34: 1460-1468.
8. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Crides A. The Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficiency, safety, and tolerability of ertapenem versus ceftriaxone for the treat5ment of community acquired pneumonia in adults. Clin Infect Dis 2002; 34: 1076-1083.
9. Roy S, Higareda I, Angel Muller E, et al. Ertapenem once a day versus piperacillin-tazobactum every 6 hors for treatment of acute pelvic infections: a prospective, multicenter, randomized double blind study. Infectious Des Obstet Gynecol 2003; 11: 1-11.
10. Tomera KM, Burdmann EA, Pamo ROG, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized double blind multicenter study. Antimicrob Agents Chemother 2002; 46: 2895-2900.
11. Teppler H, Woods G, Jonas L, et al. Safety of ertapenem for treatment of community acquired and mixed infections. In programme and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego CA, USA Washington, DC. Am Soc Microbiol. Abstract L-377, 2002; 347.
12. Kim YK, Choi H, Kim, JH Chang, et al. Synthesis and bacterial activities of LB20304: A new fluoronaphthyridone antibiotic containing novel oxime functionalized pyrrolidine. In program and abstr of the 35thth Intersci Conf Antimicrob Agents Chemother. Am Soc Microbiol. Washington DC. Abstr F204, 1995; 148.
13. Oh JI, Paek KS, Ahn MIJ, et al. in vitro and in vivo Evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother 1996; 40: 1564-1568.
14. Goldstein EJC, Citron DM, Warren Y, et al. in vitro Activity of gemifloxacin (SB 265805) against anaerobes. Antimicrob Agents Chemother 1999; 43(9): 2231-2235.
15. Yoo BK. Gemifloxacin: A new Fluoroquinolone approved for treatment of respiratory infections. Ann Pharmacol 2004; 38(7): 1226-1235.
16. Allen A, Bygate E, M vousden, et al. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob Agents Chemother 2001; 45: 540-545.
17. Zhanel GG, Homeniuk K, Nichol K, et al. The glycylcyclines: A comparitive review with the tetracyclines. Drugs 2004; 64 (1): 63-88.
18. Connell SR, Tracz DM, KH Nierhaus, Taylor DE. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 2003; 47: 3675-3681.
19. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20: 219S-223S.
20. Frampton JE. Curran MP. Tigecycline. Drugs 2005; 65 (18): 2623-2635.
21. Scheetz MH, Qi C, Warren JR, et al. in vitro Activities of various antimicrobials alone and in combination with tigecycline against Carbapenem-intermediate or- resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51(5): 1621-1626.
22. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam ain patients with complicated skin and skin structure infections: Results from a phase 3, randomised, double blind trial. Int J Infect Dis 2005; 9: 251-261.
23. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double blind phase 3 comparison study with vancomycin and aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-4666.
24. Oliva ME, Rekha A, Yellin A, et al. A multicentre trial of the efficacy and safety of Tigecycline versus Imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect. Dis 2005; 5: 88 Available at www.biomedcentral.com/1471-2334-5-88.
25. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra abdominal infections. Int J Surg 2005; 3: 35-47.
26. Thorne GM, Alder J. Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol Newsl 2002; 24: 33-39.
27. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538-2544.
28. Carpenter CF, Chambers HF. Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38: 994-1000.
29. Dvorchik BH, Brazier D, DeBruin MF, et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob agents Chemother 2003; 47: 1318-1323.
30. Wise R, Andrews JM, Ashby JP. Activity of Daptomycin against gram-positive pathogens; a comparison with other agents and the determination of a tentative breakpont. J Antimicrob Chemother 2000; 46: 563-567.
31. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: A worldwide sample of 6737 clinical gram-positive organisms. J Antimicrob Chemother 2004; 53: 669-674.
32. Cubicin ™ package insert. Lexington MA. Cubist Pharmaceuticals, Inc; 2003.
33. Kager PA, Schultz MJ, Zijlstra EE, van den Berg B, van Boxtel CJ. Arteether administration in humans: Preliminary studies of pharmacokinetics, safety and tolerance. Trans R Soc Trop Med Hyg 1994; 88(Suppl 1): S53-S54.
34. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007; 77 (Suppl 6): 81-192.
35. Thuma PE, Bhat GJ, Mabeza GF, et al. A randomized controlled trial of artemotil (β-arteether) in Zambian children with cerebral malaria. Am J Trop Med Hyg 2000; 62(4): 524-529.
36. Adjuik M, Agnamey P, Babiker P, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: A randomized multicentre trial. Lancet 2002; 359: 1365-1372.
37. Hutagalung R, Paiphun L, Ashley EA, et al. A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant plasmodium falciparum on the western border of Thailand. Malaria J 2005; 4: 46-52.
38. Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether- lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001; 64: 247-256.
39. Pandey AV, Tekwani BL, Singh L, Chauhan VS. Artemisinin, an endoperoxide antimalarial disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem 1999; 274, (27): 19383-19388.
40. Mutabingwa T, Nzila A, Mberu, E, et al. Chlorproguanil dapsone for treatment of drug resistant falciparum malaria in Tanzania. Lancet 2001; 358: 1218-1223.
41. WHO guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108 pp1-240.
42. WHO. Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated falciparum malaria in Africa 2005. Report of a Technical consultation convened by WHO. Geneva, 2004 July 1-2. WHO/HTM/MAL/ 2005.1106.
43. Hogh B, Clarke, PD, Camus D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: A randomised, double blind study. Malarone International Study Team. Lancet 2000; 356: 1888-1894.
44. Vaidya, AB. Atovaquone-proguanil combination. In: Rosenthal PJ, Ed. Antimalarial chemotherapy: Mechanisms of action, resistance, and new directions in Drug Discovery 2001; 203-218.
45. Totowa, NJ, Sunder S, Jha Tk, et al. Low dose Liposomal Amphotericin B in refractory Indian Visceral leishmaniasis: A multicenter study. Am J Trp Med Hyg 2002; 66(2): 143-146.
46. Davidson RN, de Martino, L, Gradoni L, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22: 938-943.
47. Sunder S, Jha Tk, Thakur CP, et al. Oral Miltefosine for Indian Visceral leishmaniasis. New Eng J Med 2002; 347: 1739-1746.
48. Prasad R, Kumar R, Jaiswal BP, Singh UK. Miltefosine: An oral drug for visceral leishmaniasis. Indian J Paed 2004; 71: 143-144.
49. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminisidine). An open label randomized phase II clinical study. Trans. R Soc Trop Med Hyg 2000; 94(4): 432-433.
50. Sunder S, Jha S, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. New Eng J Med2007; 356(25): 2571- 2581.
51. Yeates C. Sitamaquine (GlaxoSmithkline/Walter Reed Army Institute). Curr Opin Investig Drugs 2002; 3 (10): 1446-1452.
52. Diez E, Montage J, Ramirez E and Bernai R. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am J Trop Med Hyg 2003; 68: 384-385.
53. Prasher A, Arya R. Nitazoxanide. Indian Paed 2005; 42: 1161-1165.
54. Geary TG. Ivermectin 20 years on: maturation of a wonder drug. Trend Parasitol 2005; 21: 530-532.
55. TDR Onchocercaciasis. Seventeenth Programme Report. 2005, Progress; 2003-2004.
56. TDR. A new drug for river blindness. 2007, TDR News No. 79.
57. TDR. A suitable macrofilaricide 2000, TDR News No.62.
58. Groll AH, Gea-Banacloche J, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect Dis Clin N Am 2003; 17: 159-191.
59. Clancy CJ, Nguyen MH. in vitro Efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998; 17: 573-575.
60. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005; 49: 668-679.
61. Abuhammour W, Habte-Gaber E. Newer antifungal agents. Indian J Pediatr 2004; 71: 253-259.
62. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7(suppl 2): 8-24.
63. Ally R, Schurmann D, Kreisel W, et al. A randomized, doubleblind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454.
64. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248.
65. Supparatpinyo K, Schlamm HT. Voriconazole as Therapy for systemic Penicillium marneffei infections in AIDS Patients. Am J Trop Med Hyg 2007; 77(2): 350-353.
66. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis. 2001; 14: 685-691.
67. Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001; 21: 133S-148S.
68. Espinel-Ingroff A. in vitro Antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
69. Del Poeta M, Schell WA, Perfect JR. in vitro Antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41: 1835-1836.
70. Moudgal V, Little T, Boikov D, et al. Multiechinocandin and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-769.
71. Hernandez S, López-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-1383.
72. Borgers, M., Geffen, M.V., Ausma, J.: US20080032994A1 (2008).
73. Hu, W., Dakou, N.: WO08021944 (2008).
74. Schiller DS, Fung HB. Posaconazole: An extended-spectrum triazole antifungal agent. Clin Ther 2007; 29(9): 1862-1886.
75. Carminati, P., Salvatori, G., Luigina, R.: US20080026997A1 (2008).
76. Ibrahim, A.S., Spellberg, B.J., Edwards, J.: WO08008537 (2008).
77. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61 Suppl 1: i19-30.
78. Daneshtalab, M., Ma, C.-M.: WO08009138 (2008).
79. Balkovec, J.M., Bouffard, F.A., Tse, B., Dropinski, J., Meng, D., Greenlee, M.L., Peel, M., Fan, W., Mamai, A., Liu, H., Li, K.: US20080009504A1 (2008).